ライフサイエンスコーパス: aged @1 years

1 ncrease in non-polio AFP per 100,000 persons aged <15 years).

2 particularly great among outpatient children aged <3 years.

3 r 100 children with RSV illness) in children aged <3 years.

4 he median age was 7 years and one-third were aged <5 years.

5 , 26%, and 64%, respectively, among children aged <5 years.

6 d strongly with age, reaching 12.5% in PWHIV aged 55+ years.

7 d any PEP (MMR or IG) for nonimmune contacts aged <19 years.

8 notypes 6, 11, 16, and 18 in women and girls aged .

9 and associated demographics among US adults aged >/=18 years.

10 .0, 14.5)-approximately 17.1 million persons aged >/=21 years.

11 n-label, randomized clinical trial in adults aged >/=50 years.

12 ldren aged 6-23 months and 26% among persons aged >/=65 years.

13 lization rates were second highest in adults aged >65 years (1.7/1000 person-years).

14 pants, the median age was 51 years, 15% were aged >/=60 years, 19% were female, 29% black, and 20% Hi

15 nce daily, inhaled budesonide 400 mug (those aged <11 years 200 mug) or placebo.

16 26259 pertussis cases reported in children (aged <18 years), 27 children met the inclusion criteria.

17 2, with the greatest increases among persons aged >60 years (40%) and in southern states (32%).

18 ld Development Study, and 4448 participants (aged 16 years; 48% boys [n = 2156]) in the 1970 British

19 death were 14.8-fold higher if patients were aged <5 years, 5-fold higher if the patient had any evid

20 f Health and Development, 6683 participants (aged 16 years; 51% boys [n = 3420]) in the 1958 National

21 e data were available for 3152 participants (aged 15 years; 53% boys [n = 1660]) in the 1946 Medical

22 and stress) across community-dwelling adults aged >/=18 years across 46 countries from the World Heal

23 In children aged <3 years, acute otitis media developed in 58%, and

24 tional study, cases were defined as subjects aged >9 years admitted with influenza confirmed by polym

25 ung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozyg

26 of 14 and 20 years at 13.5% than in patients aged 14 years and younger (1.9%, P < 0.001).

27 Public Health England (PHE) for individuals aged 15 years and older, diagnosed with HIV in England a

28 Eligible patients were aged 16 years and older, had contributed data between Ja

29 Frailty is common in critically ill adults aged 18 years and older and is independently associated

30 ducted in Denmark of 6.7 million individuals aged 18 years and older from 1980 to 2014 covered more t

31 tients with newly diagnosed multiple myeloma aged 18 years and older from participating Southwest Onc

32 ics algorithm to search the EHRs of patients aged 18 years and older from the Partners Healthcare sys

33 n incident cohort of patients with psoriasis aged 18 years and older was delineated for 1998 through

34 tional study of opioid-dependent individuals aged 18 years and older who were treated in Malaysia in

35 one at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenstrom's mac

36 eserve) and its effect on outcomes for those aged 18 years and older with critical illness is unclear

37 -blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma from 165 hospi

38 xpansion JAVELIN Solid Tumor study, patients aged 18 years and older with histologically or cytologic

39 ase 2 study (BERIL-1), we recruited patients aged 18 years and older with histologically or cytologic

40 label phase 2-3 trial, we recruited patients aged 18 years and older with histologically proven, rese

41 arm, phase 2 prevention study enrolled women aged 18 years and older with postmenopausal status who h

42 42 countries, we randomly assigned patients aged 18 years and older with type 2 diabetes and establi

43 insulin-naive patients with type 2 diabetes, aged 18 years and older, who had insufficient glycaemic

44 2 years and 11 152 (76%) of 14 763 patients aged 2 years and older.

45 A nationwide study of 100,000 individuals aged 20 years and above, randomly selected in the genera

46 clinical records on 1.86 million individuals aged 20 years and older in Utah in 2015.

47 U.S. adults aged 20 years and older.

48 1094.7 million (80% UI 581.1-1686.5) people aged 35 years and older, with 666.7 million (80% UI 364.

49 machine-learning methods in 16,147 children aged 4 years and 11,080 children aged 8 years, MeDALL sh

50 Adults aged 40 years and older with type 1 diabetes of at least

51 n a general population sample of 2415 people aged 40 years and over in Australia.

52 airflow limitation in the general population aged 40 years and over.

53 This approach was also effective in contacts aged 5 years and older: 15 (10%) of 153 symptomatic cont

54 dness and 77% of vision impairment in adults aged 50 years and older in 2015.

55 of 1523 Chinese-American adults with myopia, aged 50 years and older, residing in the city of Montere

56 rofile in cognitively unimpaired individuals aged 50 years and older.

57 derate or severe vision impairment in adults aged 50 years and older.

58 ears or older and non-Indigenous Australians aged 50 years and older.

59 crossover study, we recruited men and women aged 60 years and older with angiographically proven sta

60 We recruited adults aged 60 years and older with asthma from hospital and co

61 rity study, we recruited hospitalised adults aged 60 years and older with confirmed C difficile infec

62 We did not find evidence that patients aged 65 years and older deemed fit enough for palliative

63 is a nationwide cohort study of individuals aged 65 years and older established in July 2010.

64 ashes in children aged 0-14 years and adults aged 65 years and older were most often in pedestrians,

65 Between 2015 and 2025, the number of people aged 65 years and older will increase by 19.4% (95% unce

66 The NHATS included 30202 respondents aged 65 years and older with dementia status assessment.

67 ll-prevention interventions for participants aged 65 years and older.

68 pital admissions from nursing home residents aged 65 years and older.

69 highest in children aged 1-4 years and those aged 65 years and older.

70 ,294 men and women, noninstitutionalized and aged 65 years and over were examined, and thereafter fol

71 y including all citizens in Ontario, Canada, aged 66 years and older between 2002 and 2014.

72 essed this association among 566 individuals aged 70 years and older.

73 A dengue vaccine for individuals aged 9 years and older has been licensed, but there rema

74 luation was 11 years; 20.7% of patients were aged and 36.9% were >/=18 years.

75 95% confidence interval, 12.6%-21.9%) in men aged and 17.9% (12.4%-25.0%) in those aged >

76 accuracy of PECARN (stratified into children aged <2 years and >/=2 years), CATCH, and CHALICE in pre

77 non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and IRR, 0.96; CI, .81-1.15 for those >/=2

78 Similar trends were seen in outpatients aged >/=5 years and pediatric admissions.

79 -aging." We performed a prospective study of aged (>60 years) and younger (21-40 years) inner-city pa

80 or two specific age groups-younger children (aged ) and adolescents requiring transition of

81 ological subtype of lesions seen in patients aged <50 years, and any associated clinical features.

82 Patients were non-smokers, aged >/=40 years, and using antidiabetic drugs.

83 rotease inhibitor-based regimens in children aged <3 years are currently recommended by WHO, but the

84 Adults aged >60 years are more susceptible to neuroinvasive dis

85 The oldest-old (those aged >/=80 years) are the most rapidly growing age group

86 o perform survival analysis in 2315 patients aged at diagnosis.

87 use and breast cancer in hypertensive women aged >/=55 years at 3 sites in the Kaiser Permanente hea

88 All women (n = 1012) aged >/=16 years attending our sexually transmitted infe

89 In outpatients aged <5 years, baseline TPR was 60%-80% followed by a ra

90 e included patients with first-time cataract aged >/=40 years between 1995 and 2015 and an equal numb

91 rial in previously untreated adult patients (aged >/=18 years) diagnosed with locally advanced or met

92 ss in a prospective cohort study of children aged during 2 consecutive respiratory season

93 Analyses were carried out in men and women aged 80+ years enrolled in the ilSIRENTE study (n = 286)

94 from 30 239 community-dwelling participants aged >/=45 years enrolled in the REasons for Geographic

95 years to 17.6% (95% CI 13.6%-21.5%) in those aged >/=85 years; for late AMD these figures were 0.1% (

96 ted using the parametric g-formula in adults aged 31 years from the 1982 Pelotas Birth Cohort in Braz

97 A total of 5359 subjects aged >/=40 years from the 2005-2008 National Health and

98 Children aged <2 years had an increased hazard of death (adjusted

99 Indeed, female recipients aged >/=45 years had a significantly lower graft failure

100 3166 patients (1582 [50%] aged >/=75 years) had 405 first bleeding events (n=218 g

101 Patients were eligible if they were at least aged 18 years, had Eastern Cooperative Oncology Group pe

102 Approximately 1 in 8 Americans aged >/=50 years have PNVI, with 1 in 4 reporting concur

103 ent PD cases and 118,095 comparable controls aged > 65 years in 2009 using Medicare claims data.

104 The study linked all Danish individuals aged >/=18 years in nationwide registers.

105 orthern Manhattan Study, stroke-free persons aged >/=40 years in northern Manhattan (New York, New Yo

106 alyzed by mixture models among 10,241 adults aged >/=50 years in the English Longitudinal Study of Ag

107 conditions and fair/poor health among people aged >/=65 years in the United States with and without v

108 METHODS AND Participants aged >/=18 years installed a mobile application programm

109 CV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) and >/=2 years (I

110 NAFLD prevalence among the adult population (aged >/=15 years) is projected at 33.5% in 2030, and the

111 e this possibility, we studied 40,918 older (aged >/=55 years) KT recipients (January 1, 1999 to Dece

112 Two thirds of children with IAND were aged ; less than half had pre-existing neurolo

113 19 right-handed African American individuals aged 25 years living in rural areas were recruited.

114 this prospective study, we enrolled adults (aged >/=18 years) living with HIV with CD4 cell count le

115 tional Pupil Database records of adolescents aged 15 years, living in England, with matching postcode

116 sons of Malay, Indian, and Chinese ethnicity aged 40+ years, living in Singapore.

117 o 40 weeks of gestation in nulliparous women aged >/=35 years may reduce overall rates of perinatal d

118 47 children aged 4 years and 11,080 children aged 8 years, MeDALL showed the multimorbidity of eczema

119 METHODS AND Elderly (aged >/=66 years) Medicare beneficiaries enrolled in Med

120 e of incident MCI as predicted by late-life (aged >/=70 years) mentally stimulating activities.

121 Materials and Methods Eligible individuals aged 58 years (n = 1984) living in Turin, Italy, were ra

122 udied sera samples from 3 groups of subjects aged >/=65 years (n = 16-17/group) receiving the 2008/20

123 A total of 2,197 adults aged >/=18 years, newly tested HIV positive, were enroll

124 onsisted of approximately 1.3 million adult (aged >/=19 years), non-immigrant, urban Canadians in 30

125 Cases (n = 721) were defined as patients aged >/=45 years notified with listeriosis from July 199

126 161 sickle beta(+)-thalassemia [Sbeta(+)]), aged 3 years old and over, were included at steady state

127 Patients aged 70 years old or older (n = 114) scheduled for routi

128 Patients aged >/=4 years operated for HD with TEPT between 1987 a

129 RT-in patients with cystic fibrosis who were aged 12 years or older and homozygous for the F508del-CF

130 nation treatment showed efficacy in patients aged 12 years or older with cystic fibrosis homozygous f

131 sites in 17 countries, we included patients aged 12 years or older with homozygous familial hypercho

132 Eligible participants were patients aged 12 years or older with severe eosinophilic asthma a

133 ent of seasonal allergic rhinitis in persons aged 12 years or older, routinely prescribe monotherapy

134 severe seasonal allergic rhinitis in persons aged 12 years or older, the clinician may recommend the

135 n the USA and European Union for individuals aged 12 years or older.

136 s with bone sarcoma could enrol if they were aged 12 years or older.

137 We enrolled patients aged 13 years or older with functional C1-inhibitor conc

138 In individuals aged 14 years or older, 611 cases of pesticide self-pois

139 timates show that HIV incidence among adults aged 15 years or older fell from 2.3% per year in 1996 t

140 In 2002-06, we recruited contacts aged 15 years or older of index cases with pulmonary tub

141 Eligible patients were aged 15 years or older with a diagnosis of an advanced u

142 years old was typically higher than in those aged 15 years or older.

143 We assumed no heart failure for patients aged 15 years or younger and report total incidence and

144 North America, and the Asia Pacific region, aged 16 years or older and with newly diagnosed epilepsy

145 16 fetal medicine centres, of pregnant women aged 16 years or older whose fetus had a brain abnormali

146 -dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to

147 The study included all patients, aged 16 years or older, registered on the national regis

148 All participants were aged 16 years or older.

149 Participants were aged 18 years or older and had at least one surgical wou

150 Participants included in the analyses were aged 18 years or older and had data available for linole

151 Eligible patients were aged 18 years or older and had histologically confirmed,

152 Eligible patients were aged 18 years or older and had histologically or cytolog

153 Eligible patients were aged 18 years or older and had treatment-naive, patholog

154 mised trial, we recruited whole blood donors aged 18 years or older from 25 centres across England, U

155 emtricitabine) in HIV serodiscordant couples aged 18 years or older in Kenya and Uganda that showed h

156 Patients with soft-tissue sarcoma had to be aged 18 years or older to enrol; patients with bone sarc

157 ity, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis

158 n this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia who

159 lel-group, active-controlled study, patients aged 18 years or older with Ann Arbor stage III-IV folli

160 participants were inpatients or outpatients aged 18 years or older with diabetes and a non-infected

161 Eligible patients were aged 18 years or older with Eastern Cooperative Oncology

162 We enrolled patients aged 18 years or older with HCV genotype 1, 2, 4, 5, or

163 , open-label, phase 3 study of men and women aged 18 years or older with HER2-positive unresectable,

164 Eligible patients were aged 18 years or older with histologically or cytologica

165 Postmenopausal women aged 18 years or older with histologically or cytologica

166 Eligible patients were those aged 18 years or older with ischaemic heart disease unde

167 ntrolled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, loca

168 icentre, phase 2, single-arm study, patients aged 18 years or older with metastatic or surgically unr

169 hase 3 superiority trial that enrolled women aged 18 years or older with newly diagnosed, early-stage

170 Students aged 18 years or older with no severe mental illness or

171 hase 3 equivalence trial, we recruited women aged 18 years or older with stage I-IIIa operable HER2-p

172 iority phase 3b trial, we recruited patients aged 18 years or older with symptomatic superficial-vein

173 mised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes who were rec

174 blind, randomised, controlled trial, adults (aged 18 years or older) with previously untreated, advan

175 sts compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a p

176 als enrolled participants from 11 countries, aged 18 years or older, chronically infected with HCV ge

177 Patients were aged 18 years or older, had a confirmed diagnosis of pso

178 Eligible patients were aged 18 years or older, had a diagnosis of chronic plaqu

179 Eligible patients were aged 18 years or older, had a platinum-sensitive, high-g

180 Patients were aged 18 years or older, had an Eastern Cooperative Oncol

181 arm, phase 1-2 trial, eligible patients were aged 18 years or older, had histologically confirmed rel

182 long-term extension, eligible patients were aged 18 years or older, had International Prognostic Sco

183 Patients were aged 18 years or older, had relapsed or refractory multi

184 ticipants included 3602 patients with STEMI, aged 18 years or older, who were undergoing primary perc

185 Participants aged 18 years or older, with mild to moderate intellectu

186 sease, and age-matched healthy controls, all aged 18 years or older.

187 they had chronic lymphocytic leukaemia; were aged 18 years or older; had been treated with two lines

188 Children aged 18 years or younger with type 1 diabetes and DKA an

189 We included 1,521 participants aged 20 years or older from a cross-sectional study, the

190 We did a cohort study of women in Scotland aged 20 years or older undergoing a first, single incont

191 deceased donor kidney transplant recipients aged 21 years or younger using Australia and New Zealand

192 munocompromised [HIV-infected]) or low risk (aged 3 years or older and immunocompetent [HIV-negative]

193 al done at two sites in the USA, individuals aged 3 years or older with, in each eye, best corrected

194 Individuals aged 30 years or older without known cardiovascular dise

195 he group diagnosed with type 1 diabetes when aged 30 years or younger.

196 Patients aged 4 years or older with a history of moderate to seve

197 Indigenous Australians aged 40 years or older and non-Indigenous Australians ag

198 ge-standardised prevalence in the population aged 40 years or older is about 3.5%.

199 t high risk for COPD (defined as individuals aged 40 years or older, with cumulative tobacco consumpt

200 of invasive pneumococcal disease in children aged 5 years or younger were identified through national

201 e used data from six cohorts of participants aged 50 years or older at recruitment to calculate DALYs

202 ying CriSTAL criteria to the 141 individuals aged 50 years or older indicated that frailty (OR=1.43,

203 Women aged 50 years or older who had undergone breast-conservi

204 Patients aged 50 years or older with neovascular age-related macu

205 ith 666.7 million (80% UI 364.9-997.6) being aged 50 years or older.

206 del of osteoporosis for postmenopausal women aged 55 years or older was developed with a lifetime hor

207 eported outcome data from high-risk patients aged 55 years or older with a history of cardiovascular

208 Major depression occurs in 2% of adults aged 55 years or older, and its prevalence rises with in

209 A total of 251 patients aged 6 years or older at baseline, harboring disease-cau

210 larly severe when its onset affects children aged 6 years or younger.

211 as severe or moderate to severe) for adults aged 60 years or older (n = 16,770) over 3 time periods

212 fying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, base

213 icians select the treatment goals for adults aged 60 years or older based on a periodic discussion of

214 ates of past-year abuse prevalence in adults aged 60 years or older were included in the analyses.

215 tensifying pharmacologic treatment in adults aged 60 years or older with a history of stroke or trans

216 arget patient population includes all adults aged 60 years or older with hypertension.

217 that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure pers

218 (SBP) goal of less than 150 mm Hg for adults aged 60 years or older, but the balance of benefits and

219 is of Medicare fee-for-service beneficiaries aged 65 years or older from 1999 to 2014 using the Medic

220 ed, cross-sectional study in a random sample aged 65 years or older from 7 European countries.

221 dy of Medicare fee-for-service beneficiaries aged 65 years or older hospitalized with HF, AMI, or pne

222 event Deep Vein Thrombosis included patients aged 65 years or older initiating warfarin for elective

223 The participants were 170 of 788 men aged 65 years or older with an average of 2 serum testos

224 Patients aged 66 years or older with nonbacterial AURIs.

225 rdiovascular comorbidities among individuals aged 70 years or older who were enrolled in the Einstein

226 point, randomised controlled trial, patients aged 70 years or younger with aphasia after stroke lasti

227 ntly enhanced verbal communication in people aged 70 years or younger with chronic aphasia after stro

228 trexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma.

229 ith advanced-stage epithelial ovarian cancer aged 70 years or younger.

230 2 per 100 000 individuals), and among people aged 75 years or older (51.3-99.4 per 100 000 individual

231 GI bleeding events among patient aged 75 years or older taking DOACs increased with age;

232 en that half of the major bleeds in patients aged 75 years or older were upper gastrointestinal, the

233 104 black persons and 104 white persons aged 8 years or older who had had type 1 diabetes for at

234 younger than 65 years, to 25 for individuals aged 85 years or older.

235 en-label, phase 3 study, we enrolled adults (aged >/=18 years or >/=20 years in Japan and South Korea

236 2.3; 95% CI, 1.28-4.23; P = .01; unmarried, aged >50 years: OR, 2.38; 95% CI, 1.02-5.52; P = .06).

237 compared with the reference group (married, aged >50 years: OR, 2.3; 95% CI, 1.28-4.23; P = .01; unm

238 = 0.040), and adjuvant sunitinib in patients aged <60 years (P = 0.004).

239 </=25 years and 17.9% (12.4%-25.0%) in those aged >25 years (P = .76); adjusted prevalence ratio, 0.9

240 total of 11 016 of 12 781 (88.5%) US adults aged >/=50 years participated in the National Health and

241 tics and NAFLD in 1,170 adolescent offspring aged 17 years participating in the Western Australian Pr

242 Study populations were adults (aged >/=16 years) registered with primary carer provider

243 METHODS AND We recruited adults aged >/=40 years residing in the Agincourt subdistrict o

244 .23-.85]; P = .014), and highest in persons aged >/=65 years (RR, 1.72 [95% CI, 1.25-2.35]; P < .001

245 and phenotypic data from 10 760 individuals aged 50 years that were collected by the Health and Reti

246 -34 years, 49.0% aged 35-64 years, and 17.1% aged >/=65 years) that were comparable with population e

247 ce interval [CI] = 0.28-0.93 comparing women aged >40 years to those aged 15-19 years) and male circu

248 Residual specimens from females aged <25 years undergoing chlamydia testing were collect

249 d ocular phenotyping identified early-onset (aged ) visual loss (mean [SD] best-corrected v

250 ncidence of IAE amongst Australian children (aged ) was 2.8 per 1 000 000.

251 Females aged >/=15 and males aged >/=16 years were considered adults based on average

252 Subjects aged >/=60 years were randomly assigned at a ratio of 1:

253 valsartan, and candesartan users (N=136 177) aged >/=66 years were calculated monthly, 24 months befo

254 Adults (aged >/=18 years) were eligible for the study if they ha

255 alent among syphilis patients who were male, aged >/=40 years, white, and infected with human immunod

256 We included children aged <12 years who presented to a rural clinic in wester

257 onia in the Community (EPIC) study, children aged <18 years who were hospitalized with community-acqu

258 e developed an algorithm to identify persons aged >/=16 years who were prescribed TDF-FTC for PrEP ea

259 in a retrospective cohort study of patients aged >/=18 years who initiated hemodialysis between 2004

260 806 cases of conjunctival tumor in children (aged <21 years) who were evaluated at a tertiary referra

261 We enrolled adult patients (aged >/=18 years) who had cytologically or histologicall

262 ticipants were middle-aged and older adults (aged >/=55 years) who received newly initiated depressio

263 tudies (CFAS I and CFAS II) of older people (aged >/=65 years) who were permanently registered with a

264 as built to simulate outcomes of individuals aged 50 years with well-compensated cirrhosis entering s

265 ogramme was introduced in England for adults aged 70 years with a phased catch-up programme for those

266 Youths aged with newly diagnosed T1DM or T2DM who w

267 In this study of youths aged with newly diagnosed T1DM or T2DM who w

268 Consecutive children aged <18 years with real-time polymerase chain reaction

269 This two-arm study included patients aged >/=12 years with recurrent grass pollen-induced sea

270 In Malaysian patients aged >/=12 years with severe (n = 47) and nonsevere (n =

271 All Danish individuals aged >/=18 years with a hospital (inpatient or ambulator

272 ter cohort study that enrolled 4062 patients aged >/=18 years with AMI between April 11, 2005, and De

273 Patients aged >/=18 years with noninfectious uveitis seen between

274 Adults aged >/=18 years with Schirmer tear test (without anesth

275 We randomized 416 patients aged >/=25 years with type 1 or type 2 diabetes, a serum

276 The cohort included individuals aged >/=40 years with BMD tests and self-reports of pare

277 alucorcel [CNTO-2476]) in the eyes of adults aged >/=50 years with bilateral geographic atrophy (GA)

278 We studied 41 adult and child patients aged >/=6 years with ocular misalignment owing to congen

279 Patients aged >/=60 years with treatment-naive Hodgkin lymphoma (

280 People aged >/=65 years with vision impairment reported greater

281 30 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography

282 study, we included children and adolescents (aged <18 years) with head injuries of any severity who p

283 -stage, phase 2, single-arm trial, patients (aged >/=16 years) with histologically confirmed metastat

284 randomised, phase 3 trial of adult patients (aged >/=18 years) with an Eastern Cooperative Oncology G

285 ts for the TH3RESA trial were men and women (aged >/=18 years) with centrally confirmed HER2-positive

286 We recruited patients (aged >/=18 years) with chronic myeloid leukaemia in firs

287 en-label, phase 2 trial, we enrolled adults (aged >/=18 years) with histologically confirmed recurren

288 Patients (aged >/=18 years) with metastatic urothelial carcinoma w

289 phase 1 trial, we recruited adult patients (aged >/=18 years) with newly diagnosed metastatic pancre

290 Eligible patients (aged >/=18 years) with polycythaemia vera, no palpable s

291 Eligible patients were adult women (aged >/=18 years) with recurrent measurable or evaluable

292 nd, non-inferiority trial (CLARITY), adults (aged >/=18 years) with type 1 or 2 diabetes and previous

293 We recruited adults (aged >/=18 years) with unresectable locally advanced or

294 open-label, phase 2 trial of adult patients (aged >18 years) with advanced (unresectable or metastati

295 Eighty-nine treatment-naive participants, aged >/=50 years, with active choroidal neovascularizati

296 h excess hospitalizations in elderly persons aged >/=80 years, with an excess hospitalization rate pe

297 al, consenting patients with type 2 diabetes aged >18 years, with waist circumference >94 (males) or

298 material of age-and-sex-matched individuals (aged >45 years, with a normal blood count and no history

299 pharyngeal aspirates collected from children aged <5 years within 24 hours of hospital admission duri

300 omised controlled trial, we enrolled adults (aged >/=18 years) within 24 h of presenting to the emerg